Strategies for immunotherapy of cancer

Advances in Immunology

Volumn 75, Issue , 2000, Pages 235-282

  Melief, Cornelis J M ^a   Toes, René E M ^a   Medema, Jan Paul ^a   Van Der Burg, Sjoerd H ^a   Ossendorp, Ferry ^a   Offringa, Rienk ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD28 ANTIGEN; CD4 ANTIGEN; CYTOKINE; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DENDRITIC CELL; HELPER CELL; HUMAN; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR IMMUNITY; VACCINATION;

EID: 0033916260     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0065-2776(00)75006-1     Document Type: Review

References (283)

1. Aarnoudse, C. A., van den Doel, P. B., Heemskerk, B., and Schrier, P. I. (1999). Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int. J. Cancer 82, 442-448.
2. Abril, E., Real, L. M., Serrano, A., Jimenez, P., Garcia, A., Canton, J., Trigo, I., Garrido, F., and Ruiz-Cabello, F. (1998). Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell fine. Cancer Immunol. Immunother. 47, 113-120.
3. Agrawal, B., Krantz, M. J., Parker, J., and Longenecker, B. M. (1998). Expression of MUC1 mucin on activated human T cells: Implications for a role of MUC1 in normal immune regulation. Cancer Res, 58, 4079-4081
4. Akbari, O., Panjwani, N., Garcia, S., Taseon, R., Lowrie, D., and Stockinger, B. (1999). DNA vaccination: Transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. 189, 169-178.
5. Albert, M. L., Darnell, J. C., Bender, A., Francisco, L. M., Bhardwaj, N., and Darnell, R. B. (1998a). Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nature Med. 4, 1321-1324.
6. Albert, M. L., Pierce, S. F. A., Francisco, L. M., Santer, B., Roy, P., Silberstein, R. L., and Bhardwai, N. (1998b). Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to CTL. J. Exp. Med. 188, 1359-1368.
7. Albert, M. L., Santer, B., and Bhardwaj, N. (1998). Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89.
8. + T cells. J. Immunol. 144, 3980-3986.
9. Allison, J. P. (1994). CD28-B7 interactions in T cell activation. Curr. Opin. Immunol. 6, 414-419.
10. Altman, J. D., Moss, P., Goulder, P., Barouch, D. H., McHeyzer, W. M., Bell, J. I., McMichael, A. J., and Davis, M. M. (1996). Phenotypic analysis of antigen specific T lymphocytes. Science 274, 94-96.
11. Amakawa, R., Hakem, A., Kundig, T. M., Matsuyama, T., Simard, J. J. L., Timms, E., Wakeham, A., Mittruecker, H. W., Griesser, H., Takimoto, H., H., Schmits, R., Shahinian, A., Ohashi, P. S., Penninger, J. M., and Mak, T. W. (1996). Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 84, 551-562.
12. Apostolopoulos, V., Karanikas, V., Haurum, J. S., and McKenzie, I. F. (1997). Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. 159, 5211-5218.
13. Asai, O., Longo, D. L., Tian, Z. G., Hornung, R. L., Taub, D. D., Ruscetti, F. W., and Murphy, W. J. (1998). Suppression of GVHD and amplification of graft versus tumor effects by activated NK cells after allogeneic bone marrow transplantation. J. Clin. Invest. 101, 1835-1842.
14. Bakker, A. B., Marland, G., de Boer, A. J., Huijbens, R. J., Danen, E. H., Adema, G. J., and Figdor, C. G. (1995). Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 55, 5330-5334.
15. Beekman, N., van Veelen, P. A., van Hall, T., Camps, M., Drijfhout, J. W., Kloetzel, P. M., Melief, C. J. M., and Ossendorp, F. (2000). Flanking amino acids influence C-terminal cleavage preference for CTL epitope generation by the 20S proteasome. J. Immunol. 164, 1898-1905.
16. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., and Duke, R. C. (1995). A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632
17. + T cells in the liver during the control and resolution phases of influenza pneumonia. Proc. Natl Acad. Sci. USA 95, 13812-13817.
18. Benitez, R., Godelaine, D., Lopez-Nevot, M. A., Brasseur, F., Jimenez, P., Marchand, M., Oliva, M. R., Van Baren, N., Cabrera, T., Andry, G., Landry, C., Cabello, F. R., Boon, T., and Garrido, F. (1998). Mutations of the β2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52, 520-529.
19. + T cell help. J. Exp. Med. 186, 65-70.
20. Bennett, S. R. M., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., and Heath, W. R. (1998). Help for cytotoxic T lymphocyte responses is mediated by CD40 signalling. Nature 393, 478-480.
21. Bevan, M. J. (1995). Antigen presentation to cytotoxic T lymphocytes in vivo. J. Exp. Med. 182, 639-641.
22. 1. Immunity 3, 87-98.
23. Boniface, J. J., Rabinowitz, J. D., Wülfing, C., Hampl, J., Reich, Z., Altman, J. D., Kantor, K. M., Beeson, C., McConnell, H. M., and Davis, M. M. (1998). Initiation of signal transduction through the TCR requires the peptide multivalent engagement of MHC ligands. Immunity 9, 459-466.
24. Boon, T., Cerottini, J. C., Van den Eynde, B., Van der Bruggen, P., and Van Pel, A. (1994). Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365.
25. Brossart, P., Stuhler, G., Flad, T., Stevanovic, S., Rammensee, H. G., Kanz, L., and Brugger, W. (1998). Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58, 732-736
26. Brossart, P., Heinrich, K. S., Stuhler, G., Behnke, L., Reichardt, V. L., Stevanovic, S., Muhm, A., Rammensee, H. G., Kanz, L., and Brugger, W. (1999). Identification of HLA-A2-restricted T cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93, 4309-4317.
27. Cabrera, T., Collado, A., Fernandez, M. A., Ferron, A., Sancho, J., RuizCabello, F., and Garrido, F. (1998). High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 52, 114-123.
28. Campbell, M. J., Carroll, W., Kon, S., Thielemans, K., Rothbard, J. B., Levy, S., and Levy, R. (1987). Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. Immunol. 139, 2825-2833.
29. Campbell, M. J., Esserman, L., Byars, N. E., Allison, A. C., and Levy, R. (1990). Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. 145, 1029-1036.
30. Cassel, D., and Forman, J. (1988). Linked recognition of helper and cytotoxic determinants for the generation of CTL. Ann. NY Acad. Sci. 532, 51-60.
31. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., and Alber, G. (1996). Ligation of CD40 on dendritic cells triggers production of high levels of IL-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184, 747-752.
32. Cerutti, A., Schaffer, A., Shah, S., Zan, H., Liou, H. S., Goodwin, R. G., and Casali, P. (1998). CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells. Immunity 9, 247-256.
33. Chambers, C. A., and Allison, J. P. (1997). Costimulation in T cell responses. Curr. Opin. Immunol. 9, 396-404.
34. Chang, M. H., Chen, C. J., Lai, M. S., et al. (1997). Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med. 336, 1855-1859.
35. Chaux, P., Vantomme, V., Conlie, P., Boon, T., and Van der Bruggen, P. (1998). Estimation of the frequencies of anti-MAGE-3 cytolytic T lymphocyte precursors in blood from individuals without cancer. Int. J. Cancer 77, 538-542.
36. + T lymphocytes. J. Exp. Med. 189, 767-777.
37. Chen, H. L., and Carbone, D. P. (1997). p53 as a target for anti-cancer immunotherapy. Mol. Med. Today 3, 160-167.
38. Chen, J. J., Sun, Y., and Nabel, G. J. (1998). Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282, 1714-1717.
39. Chen, Y. T., Scanlan, M. J., Sahin, U., Türeci, Ö., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., and Old, L. J. (1997). A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94, 1914-1918.
40. Clemente, C., Rao, S., Lupetti, R., Tragni, G., Pisarra, P., Bersani, I., Parminai, G., Mihm, M. C., and Sensi, M. (1998). Immunohistochemical analysis of the T cell receptor-B chain variable regions expressed by T-lymphocytes infiltrating primary human melanoma. Lab. Invest. 78, 619-627.
41. Coughlin, C. M., Salhany, K. E., Gee, M. S., La Temple, D. C., Kotenko, S., Ma, S. J., Gri, G., Wysocka, M., Kim, J. E., Liu, L., Liao, F., Farber, J. M., Pestka, S., Trinchieri, G., and Lee, W. M. F. (1998a). Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9, 25-34.
42. Coughlin, C. M., Salhany, K. E., Wysocka, M., Aruga, E., Kurzawa, H., Chang, A. E., Hunter, C. A., Fox, J. C., Trinchieri, G., and Lee, W. M. F. (1998b). IL-12 and IL-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101, 1441-1452.
43. Darnell, R. B., and DeAngelis, L. M. (1993). Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 341, 21-22.
44. Darnell, R. B. (1996). Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer immunity and the brain. Proc. Natl. Acad. Sci. USA 93, 4529-4536.
45. Davis, M. (1999). Presentation on Keystone Symposium on Tolerance and Autoimmunity, March 26-April 1, Keystone, CO.
46. De Benedette, M. A., Shahinian, A., Mak, T., and Watts, T. H. (1997). Costimulation of CD28-T lymphocytes by 4-1 BB ligand. J. Immunol. 158, 551-559.
47. De Bruijn, M. L. H., Schuurhuis, D. H., Vierboom, M. P. M., Vermeulen, H., De Cock, K. A. J., Ooms, M. E., Ressing, M. E., Toes, R. E. M., Franken, K. L. M. C., Drijfhout, J. W., Ottenhoff, T. H. M., Offringa, R., and Melief, C. J. M. (1998). Immunization with HPV16 oncoprotein-loaded DC as well as protein in adjuvant induces MHC class I restricted protection to HPV16-induced tumor cells. Cancer Res. 58, 724-731.
48. De Gruijl, T. D., Bontkes, H. J., Stukart, M. J., Walboomers, J. M. M., Remmink, A. J., Verheijen, R. H. M., Helmerhorst, T. J. M., Meijer, C. J. L. M., and Scheper, R. J. (1996). T cell proliferative responses against HPV16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J. Gen. Virol. 77, 2183-2191.
49. De Gruijl, T. D., Bontkes, H. J., Walboomers, J. M. M., Stukart, M. J., Doekhie, F. S., Remmink, A. J., Helmerhorst, T. J. M., Verheijen, R. H. M., Duggan-Keen, M. F., Stern, P. L., Meijer, C. J. L. M., and Scheper, R. J. (1998). Differential T helper responses to HPV16 E7 related to viral clearance or persistence in patients with cervical neoplasia. Cancer Res. 58, 1700-1706.
50. DeLeo, A. B., Jay, G., Appella, E., DuBois, G. C., Law, L. W., and Old, L. J. (1979). Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA 76, 2420-2423.
51. DeLeo, A. B. (1998). P53-based immunotherapy of cancer. Crit. Rev. Immunol. 18, 29-35.
52. Delon, J., Grégoire, C., Malissen, B., Darche, S., Lemaitre, F., Kourilsky, P., Abastado, J. P., and Trautmann, A. (1998). CD8 expression allows T cell signaling by monomeric peptide-MHC complexes. Immunity 9, 467-473.
53. Diehl, L., Den Boer, A. Th., Schoenberger, S. P., Van der Voort, E. I. H., Schumacher, T. N. M., Melief, C. J. M., Offringa, R., and Toes, R. E. M. (1999). CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Med. 5, 774-779.
54. Domenech, N., Henderson, R. A., and Finn, O. J. (1995). Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol. 155, 4766-4774.
55. Drakesmith, H., O'Neil D., Schneider, S. C., Binks, M., Medd, P., Sercarz, E., Beverley, P., and Chain, B. (1999). In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen. Proc. Natl. Acad. Sci. USA 95, 14903-14908
56. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
57. Dunbar, P. R., Ogg, G. S., Chen, J., Rust, N., Van der Bruggen, P., and Cerundolo, V. (1998). Direct isolation, phenotyping and cloning of low frequency antigen-specific CTL from peripheral blood. Current Biol. 8, 413-416.
58. Eshhar, Z. (1997). Tumor-specific T-bodies: Towards clinical application. Cancer Immunol. Immunother. 45, 131-136.
59. Evans, E. M., Man, S., Evans, A. S., and Borysiewicz, L. K. (1997). Infiltration of cervical cancer tissue with HPV-specific CTL. Cancer Res. 57, 2943-2950.
60. Feltkamp, M. C. W., Smits, H. L., Vierboom, M. P. M., Minnaar, R. P., de Jongh, B. M., Drijfhout, J. W., Ter Schegget, J., Melief, C. J. M., and Kast, W. M. (1993). Vaccination with CTL epitope containing peptide protects against a tumor induced by HPV16-transformed cells. Eur. J. Immunol. 23, 2242-2249.
61. Flad, T., Spengler, B., Kalbacher, H., Brossart, P., Baier, D., Kaufmann, R., Bold, P., Metzger, S., Blüggel, Meyer, H. E., Kurz, B., and Müller, C. A. (1998). Direct identification of MHC class I-bound tumor-associated peptide antigens of a renal carcinoma cell fine by a novel mass spectrometric method. Cancer Res. 58, 5803-5811.
62. Funakoshi, S., Longo, D. L., Beckwith, M., Conley, D. K., Tsarfaty, G., Tsarfaty, I. et al. (1994). Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83, 2787-2794.
63. Gallahger, W. M., and Brown, R. (1999). P53-oriented cancer therapies: Current progress. Ann. Oncol. 10, 139-150.
64. Gallimore, A., Fumrese, T., Hengartner, H., Zinkernagel, R. M., and Rammensee, H. G. (1998). Protective immunity does not correlate with the hierarchy of virus-specific CTL responses to naturally processed peptides. J. Exp. Med. 187, 1647-1657.
65. Gao, S. J., Kingsley, L., Li, M., Zheng, W., Parravicini, C., Ziegler, J., Newton, R., Rinaldo, C. R., Saah, A., Phair, J., Detels, R., Chang, Y., and Moore, P. S. (1996). KSHV antibodies among Americans, Italians and Ugenands with and without Kaposi's sarcoma. Nature Med. 2, 925-929.
66. Garrido, F., Cabrera, T., Lopez-Nevot, M. A., and Ruiz-Cabello, F. (1995). HLA class I antigens in human tumors. Adv. Cancer Res. 67, 155-195.
67. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Perez-Villar, J. J., Lopez-Botet, M., Duggan-Keen, M., and Stern, P. L. (1997). Implication for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18, 89-95.
68. Geier, E., Pfeifer, G., Wilm, M., Lucchiari-Hartz, M., Baumeister, W., Eichmann, K., and Niedermann, G. (1999). A giant protease with potential to substitute for some functions of the proteasome. Science 283, 978-981.
69. Gil-Torregrosa, B. C., Castano, A. R., and Del Val, M. (1998). Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the trans-Golgi network protease furin. J. Exp. Med. 188, 1105-1106.
70. Gold, P. (1967). Circulating antibodies against carcinoembryonic antigens of the human digestive system. Cancer 20, 1663-1667.
71. Gong, J., Chen, D., Kashiwaba, M., Li, Y., Chen, L., Takeuchi, H., Qu, H., Rowse, G. J., Gendler, S. J., and Kufe, D. (1998). Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA 95, 6279-6283.
72. Goulmy, E. (1997). Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immuno-therapy. Immunol. Rev. 157, 125-140.
73. Gravestein, L. A., and Borst, J. (1998). Tumor necrosis factor receptor family members in the immune system. Sem. Immunol. 10, 423-434.
74. Greenberg, P. D. (1991). Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elemenation of tumor cells. Adv. Immunol. 49, 281-355.
75. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., and Ferguson, T. A. (1995). Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192
76. Griffith, T. S., Chin, W. A., Jackson, G. C., Lynch, D. H., and Kubin, M. Z. (1998). Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161, 2833-2840.
77. Gurunathan, S., Irvine, K. R., Wu, C. Y., Cohen, J., Thomas, E., Prussin, C., Restifo, N. P., and Seder, R. A. (1998). CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infections and tumor challenge. J. Immunol. 161, 4563-4571.
78. Hamad, A. R. A., O'Herrin, S. M., Lebowitz, M. S., Srikrisknau, A., Bieler, J., Schneck, J., and Pardoll, D. (1998). Potent T cell activation with dimeric peptide-MHC class II ligand: The role of the CD4 coreceptor. J. Exp. Med. 188, 1633-1640.
79. Hammel, P., Boissier, B., Chaumette, M. T., Piedbois, P., Rotman, N., Koujoumdjian, Lubin, R., Delchier, J. C., and Soussi, T. (1997). Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 40, 356-361.
80. Hanabuchi, S., Koyaniagi, M., Kawasaki, A., Shinohara, N., Matsuzawa, A., Nishimura, Y., Kobayaski, Y., Yonehara, S., Yagita, H., and Okumura, K. (1994). Fas and its ligand in a general mechanism of T cell mediafted cytotoxicity. Proc. Natl. Acad. Sci. USA 91, 4930-4934.
81. Heath, W. R., Kurts, C., Miller, J. F. A. P., and Carbone, F. (1998). Cross-tolerance: A pathway for inducing tolerance to peripheral tissue antigens. J. Exp. Med. 187, 1549-1553.
82. Hellström, I., Hellström, K., and Chen, L. (1995). Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev. 145, 123-145.
83. Henderson, R. A., Cox, A. L., Sakaguchi, K., Appella, E., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H. (1993). Direct identification of an endogenous peptide recognized by multiple HLA-A2. 1-specific CTL. Proc. Natl. Acad. Sci. USA 90, 10275-10279.
84. + T lymphocytes producing TNFα spots in response to peptide antigens. J. Immunol. Meth. 203, 141-152.
85. Heslop, H. E., Ng C. Y., Li, C., Smith, C. A., Loftin, S. K., Krance, R. A., Brenner, M. K., and Rooney, C. M. (1996). Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med. 2, 551-555.
86. Hess, S., Gottfried, E., Smola, H., Grunwald, U., Schuchmann, M., and Engelmann, H. (1998). CD40 induces resistance to TNF-mediated apoptosis in a fibro-blast cell line. Eur. J. Immunol. 28, 3594-3604.
87. Hiesse, C., Rieu, P., Kriaa, F., Larue, J. R., Goupy, C., Neyrat, N., and Charpentier, B. (1997). Malignancy after renal transplantation analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc. 71, 517-520.
88. + T cells. Cancer Res. 58, 5066-5070.
89. Hirano, A., Longo, D. L., Ferris, D. K., Taub, D. D., Young, L. S., Eliopoulos, A. G., Cullen, N., Macartney, J., Fanslow, W. C., and Murphy, W. J. (1999). Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 93, 2999-3007.
90. Ho, G. Y. F., Bierman, R., Beardsley, L., Chang, C. J., and Burk, R. D. (1998). Natural history of cervicovaginal papillomavirus infection in young women. N. Eng. J. Med. 338, 423-428.
91. Hodge, J. W., McLaughlin, J. P., Kantor, J. A., and Schlom, J. (1997). Diversified prime and boost protocols using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to enhance T cell immunity and antitumor responses. Vaccine 15, 759-768
92. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. (1991). P53 mutations in human cancer. Science 253, 49-53.
93. Hooijberg, E., Sein, J. J., van den Berk, P. C., Hart, A. A., Van der Valk, M. A., Kast, W. M., Melief, C. J. M., and Hekman, A. (1995). Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin-2. Cancer Res. 55, 2627-2634.
94. Horie, R., and Watanabe, T. (1998). CD30: Expression and function in health and disease. Semin. Immunol. 10, 457-470.
95. Houbiers, J. G. A., Nijman, H. W., Van der Burg, S. H., Drijfhout, J. W., Kenemans, P., van de Velde, C. J. H., Brand, A., Momburg, P., Kast, W. M., and Melief, C. J. M. (1993). In vitro induction of human cytotoxic T Lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23, 2072-2077.
96. Houbiers, J. G., van der Burg, S. H., van de Watering, L. M., Tollenaar, R. A., Brand, A., van de Velde, C. J., and Melief, C. J. (1995). Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br. J. Cancer 72, 637-641.
97. Hsu, F. J., Caspar, C. B., Czerwinski, D., Kwak, L. W., Liles, T. M., Syrengelas, A., Taidi-Laskowski, B., and Levy, R. (1997). Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89, 3129-3135.
98. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. (1996). Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52-58.
99. Huang, A. Y. C., Golumbek, P., Ahmad-Zadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965.
100. + T cells in anti-tumor immune response. J. Exp. Med. 188, 2357-2368.
101. Hurtado, J. C., Kim, Y. J., and Kwon, B. S. (1997). Signals through 4-1 BB are costimulatory to previously activated splenic T cells and inhibit activation induced cell death. J. Immunol. 158, 2600-2609.
102. Hurwitz, A. A., Yu, T. F. Y., Leach, D. R., and Allison, J. P. (1998). CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95, 10067-10071.
103. Ikeda, H., Lethé, B., Lehmann, F., Van Baren, N., Baurain, J.-F., De Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T., and Coulie, P. G. (1997). Cytolytic T cells expressing NK inhibitory receptor P58.2 recognize on a melanoma metastasis lacking HLA-Cw7, an antigen encoded by a gene which is preferentially expressed in tumors. Immunity 6, 199-208.
104. Irmler, M., Thome, M., Habne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J. L., Schröter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L. E., and Tschopp, J. (1997). Inhibition of death receptor signals by cellular FLIP. Nature 388, 190-195.
105. Irvine, K. R., Chamberlain, R. S., Shulman, E. P., Surman, D. R., Rosenberg, S. A., and Restifo, N. P. (1997). Enhancing efficacy of recombinant anticancer vaccines with prime/ boost regimens that use two different vectors. J. Natl. Cancer Inst. 89, 1595-1601.
106. Jäger, E., Ringhoffer, M., Dienes, H. P., Brand, M., Karbach, J., Jäger, D., Ilsemann, C., Hagedorn, M., Oesch, F., and Knuth, A. (1996). GM-CSF enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer 67, 54-62.
107. Jäger, E., Ringhoffer, M., Altmannsberger, M., Brand, M., Karback, J., Jäger, D., Oesch, F., and Knuth, A. (1997). Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastative melanoma. Int. J. Cancer 71, 142-147.
108. Jäger, E., Chen, Y. T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jäger, D., Brand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L. J., and Knuth, A. (1998). Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187, 265-270.
109. Johnson, A., France, J., Sy, M. S., and Harding, C. V. (1998). Down-regulation of the transporter for antigen presentation, proteasome subunits and MHC class I in tumor cell lines. Cancer Res 58, 3660-3667.
110. Jondal, M., Schirmbeck, R., and Reimann, J. (1996). MHC class I-restricted CTL responses to exogenous antigens. Immunity 5, 295-302.
111. Kägi, D., Vignaux, F., Ledermann, B., Bärki, K., Depraetere, V., Nagata, S., Hengartner, H., and Golstein, P. (1994). FAS and perform pathways as major mechanisms of T cell mediated cytotoxicity. Science 265, 528-530.
112. Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., and Schreiber, R. D. (1998). Demonstration of an interferon-γ dependent tumor surveillance systems in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95, 7556-7561.
113. Kass, E., Schlom, J., Thompson, J., Guadagni, F., Graziano, P., and Greiner J. W. (1999). Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59, 676-683.
114. Kast, W. M., Offringa, R., Peters, P. J., Voordouw, A. C., Meloen, R. H., Van der Eb, A. J., and Melief, C. J. M. (1989). Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59, 603-614.
115. Kataoka, T., Schr&ouacte;ter, M., Hahne, M., Schneider, P., Irmler, M., Thome, M., Froelich, C. J., and Tschopp, J. (1998). FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs and gamma irradication. J. Immunol. 161, 3936-3942.
116. Kedes, D. H., Operskalski, E., Busch, M., Kohn, R., Flood, J., and Ganem, D. (1996). The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus: Distribution of infection in KS risk groups and evidence for sexual transmission. Nature Med. 2, 918-921.
117. Kiener, P. A., Moran-Davis, P., Rankin, B. M., Wahl, A. F., Ajuffo, A., and Hollenbaugh, P. (1995). Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J. Immunol. 155, 4917-4925.
118. Kim, C. J., Prevette, T., Cormier, J., Overwijk, W., Roden M., Restifo, N. P., Rosenberg, S. A., and Marincola, F. M. (1997). Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro J. Immunother. 20, 276-286
119. H1 responses. Eur. J. Immunol. 28, 881-890.
120. King, C. A., Wills, M. R., Hamblin, T. J., and Stevenson, F. K. (1993). Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells. Cell. Immunol 147, 411-424
121. Klas, C., Debatin, K. M., Jonker, R. R., and Krammer, P. H. (1993). Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 5, 625-630
122. Koch, F., Stanzl, U., Jennewein, P., Janke, K., Heufler, C., Kampgen, E., Romani, N., and Schuler, G. (1996). High level IL-12 production by murine dendritic cells: Upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184, 741-746.
123. Kolb, H. J., and Holler, E. (1997). Adoptive immunotherapy with donor lymphocyte transfusions. Curr. Opin. Oncol 9, 139-145.
124. Kotera, Y., Fontenot, D. G., Pecher, G., Metzgar, R. S., and Finn, O. (1994). Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res. 54, 2856-2860.
125. Krammer, P. (1999). CD95 (APO-1/Fas)-mediated apoptosis: Live and let die. Adv. Immunol. 71, 163-210.
126. Krause, A., Guo, H. F., Latouche, J. B., Tan, C., Cheung, N. K., and Sadelain, M. (1998). Antigen-dependent CD28 signalling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188, 619-626.
127. Kronin, V., Winkel, K., Suss, G., Kelso, A., Heath, W., Kirberg, J., von Boehmer, H., and Shortman, K. (1996). A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production. J. Immunol. 157, 3819-3827.
128. + presentation of self-antigens and favors autoimmunity. J. Exp. Med. 186, 2057-2062.
129. + T cells induced by cross-presentation of self-antigens involves signaling through CD95 (fas, Apo-1). J. Exp. Med. 188, 415-420.
130. Kurts, C., Carbone, F. R., Krummel, M. F., Koch, K. M., Miller, J. F. A. P., and Heath, W. R. (1999). Signaling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 398, 341-344.
131. Lane, D. P. (1994). p53 and human cancer. British. Med. Bull. 50, 582-599.
132. Lens, S. M. A., Tesselaar. K., van Oers, M. H. J., and Van Lier, K. A. W. (1998). Control of lymphocyte function through CD27-CD70 interactions. Semin. Immunol. 10, 491-499.
133. Lethé, B., Lucas, S., Michaux, L., De Smet, C., Godelaine, D., Serrano, A., De Plaen, E., and Boon, T. (1998). LAGE-1, a new gene with tumor specificity. Int. J. Cancer 76, 903-908.
134. Lezzi, G., Karjalainen, K., and Lanzavecchia, A. (1998). The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8, 89-95.
135. Lindner, R., and Unanue, E. R. (1996). Distinct MHC class II complexes generated by separate processing pathways. EMBO J. 15, 6910-6920.
136. Loenen, W. A. M. (1998). CD27 and TNFR relatives in the immune system: Their role in health and disease. Semin. Immunol. 10, 407-422.
137. Lowin, B., Hahne, M., Mattman, C., and Tschopp, J. (1994). Cytotoxic T cell cytotoxicity is mediated through perform and FAS lytic pathways. Nature 370, 650-653.
138. Lubin, R., Schlichtholz, B., Teilland, J. L., Garay, E., Bussel, A., Wild, C. P., and Soussi, T. (1995a). P53 antibodies in patients with various types of cancer: Assay, identification and characterization. Clin. Cancer Res. 1, 1463-1469.
139. Lubin, R., Zalcman, G., Bouchet, L., Trédamiel, J., Legros, Y., Cazals, D., Hirsch, A., and Soussi, T. (1995b). Serum p53 antibodies as early markers of lung cancer. Nature Med. 1, 701-702.
140. Luxton, J. C., Rowe, A. J., Cridland, J. C., Coletart, T., and Sheperd, P. S. (1996). Proliferative T cell response to the HPV16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. J. Gen. Virol. 77, 1585-1593.
141. Lynch, R. G., Graff, R. J., Sirisinha, S., Simms, E. S., and Eisen, H. N. (1972). Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. USA 69, 1540-1544.
142. Mackey, M. F., Gunu, J. R., Ting, P. P., Kukutani, H., Dranoff, G., Noelle, K. J., and Barth, R. J. (1997). Protective immunity induced by tumor vaccines requires interactions between CD40 and its ligand, CD154. Cancer Res. 57, 2569-2574.
143. Mackey, M. F., Gunn, J. R., Maliszewski, C., Kikutani, H., Noelle, R. J., and Barth, R. J. (1998). Dendritic cells require maturation via CD40 to generate protective anti-tumor immunity. J. Immunol. 161, 2094-2098.
144. Magarian-Blander, J., Ciborowski, P., Hsia, S., Watkins, S. C., and Finn, O. (1998). Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumorspecific peptide epitope on the epithelial antigen MUC1. J. Immunol. 160, 3111-3120.
145. Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Bodkin, D., Schuller, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T. M., Dallaire, B. K., et al. (1997). IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non Hodgkin's lymphoma. Blood 90, 2188-2195.
146. + CTL in association with histocompatibility leukocyte antigen DK II. J. Exp. Med. 189, 871-876.
147. Manoury, B., Hewitt, E. W., Morrice, N., Dando, P. M., Barrett, A. J., and Watts, C. (1998). An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 396, 695-699.
148. Manz, R., Assenmacher, M., Pfluger, E., Miltenyi, S., and Radbruch, A. (1995). Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. Proc. Natl. Acad. Sci. USA 92, 1921-1925.
149. Marchand, M., Weynants, P., Rankin, E., Arienti, F., Belli, F., Parmiani, G., Cascinelli, N., Bourlond, A., Vanwijck, R., Humblet, Y., et al. (1995). Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63, 883-885.
150. Marshall, J. L., Hawkins, M. J., Tsang, K. Y., Richmond, E., Pedicano, J. E., Zhu, M. Z., and Schlom, J. (1999). Phase I study in cancer patients of a
151. Matzinger, P. (1994). Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045.
152. Matzinger, P. (1998). An innate sense of danger. Semin. Immunol. 10, 399-415.
153. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzi, C. Falo, L. D., Melief, C. J. M., Ildstad, S. T., Kast, W. M., DeLeo, A. B., and Lotze, M. T. (1995). Bone-marrow-derived DC pulsed with synthetic tumour peptides elicits protective and therapeutic antitumour immunity. Nature Med. 1, 1297-1301.
154. McArthur, J. G., and Mulligan, R. C. (1998). Induction of protective anti-tumor immunity by gene-modified dendritic cells. J. Immunother. 21, 41-47.
155. McCormick, A. A., Kumagai, M. H., Hanley, K, Turpen T. H., Hakim I, Grill, L. K., Tuse, D., Levy, S., and Levy, R. (1999). Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc. Natl. Acad. Sci. USA 96, 703-708.
156. Medema, J. P., de Jong, J., Van Hall, T., Melief, C. J. M., and Offringa, R. (1999). Immune escape of tumors in vivo by expression of C-FLIP. J. Exp. Med., 190, 1033-1038.
157. Melero, I., Shuford, W. W., Ashe-Newby, S., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., and Chen, L. (1997). Monoclonal antibodies against the 4-1 BB T cell activation molecule eradicate established tumors. Nature Med. 3, 682-685.
158. Melief, C. J. M. (1992). Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58, 143-175.
159. Mitchell, D. A., Noir, S. K., and Gilboa, E. (1998). Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells. Eur. J. Immunol. 28, 1923-1933.
160. Morecki, S., Yacovlev, E., Diab, A., and Slavin, S. (1998). Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res. 58, 3891-3895.
161. Motta, I., Lone, Y. C., and Kourilsky, P. (1998). In vitro induction of CTL with complexes of peptide and recombinant MHC class I molecules coated onto beads: Role of TCR/ ligand density. Eur. J. Immunol. 28, 3685-3695.
162. Münz, C., Obst, R., Ösen, W., Stevanovic, S., and Rammensee, H. G. (1999). Alloreactivity as a source of high avidity peptide-specific human CTL. J. Immunol. 162, 25-34.
163. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, Slansky J, and Ahmed R. (1998). Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection. Immunity 8, 177-187.
164. Murphy, W. J., Funakoshi, S., Beckwith, M., Rushing, S. E., Conley S. K., Armitage, R. J., et al. (1995). Antibodies to CD40 prevent Epstein-Barr virus-mediated human B cell lymphomagenesis in SCID mice given human PBL. Blood 86, 1946-1953.
165. Mutis, T., Verdijk, R., Schrama, E., Esendam, B., Brand, A., and Goulmy, E. (1999). Feasibility of immunotherapy of relapsed leukemia with ex vivogenerated CTL specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 93, 2336-2341.
166. Muy-Rivera, M., Lemon, M., Funatake, C., and Weinberg, A. D. (1998). Enhancement of antitumor immunity by engaging the OX40 receptor (CD134) in vivo. Am. Assoc. Cancer Res. Meeting Abstracts. 3610, 193.
167. Nagata, S. (1997). Apoptosis by death factor. Cell 88, 355-365.
168. Nair, S. K., Boczkowski, D., Morse, M., Cumming, R. I., Lyerly, H. K., and Gilboa, E. (1998). Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol, 16, 364-369.
169. + T cells infiltrated within cancer cells nests as a prognostic factor in human colorectal cancer. Cancer Res. 58, 3491-3494.
170. Nelson, C. A., Vidafsky, I., Viner, N. J., Gross, M. L., and Unanue, E. R. (1997). Aminoterminal trimming of peptides for presentation on major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 94, 628-633.
171. Nestlé, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. (1998). Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332.
172. Newstead, C. G. (1998). Assessment of risk of cancer after renal transplantation. Lancet 351, 610-612.
173. Nussbaum, A. K., Dick, T. P., Keilholz, W., Schirle, M., Stevanovic, S., Dietz, K., Heinemeyer, W., Groll, M., Wolf, D. H., Huber, R., Rammensee, H. G., and Schild, H. (1998). Cleavage motifs of the yeast 20S proteasome β subunits deduced from digest of enolase 1. Proc. Natl Acad. Sci. USA 95, 12504-12509.
174. Obst, R., Münz, C., Stevanovic, S., and Rammensee, R. G. (1998). Allo- and self-restricted CTL against a peptide library: Evidence for a functionally diverse allo-restricted T cell repertoire. Eur. J. Immunol. 28, 2432-2443.
175. Offringa, R., Toes, R. E. M., Ressing, M. E., De Bruijn, M. L. H., and Melief, C. J. M. (1999). T cell-mediated immunotherapy of cancer. In "Textbook of Malignant Haematolgy," pp. 447-461. Martin Dunitz, Cambridge Univ. Press, UK.
176. Ogg, G. S., Dunbar, P. R., Romero, P., Chen, J. L., and Cerundolo, V. (1998). High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in Autoimmune Vitiligo. J. Exp. Med. 188, 1203-1208.
177. O'Reilly, R. J., Small, T. N., Papadopoulos, E., Lucas, K., Lacerda, J., and Koulova, L. (1998). Adoptive immunotherapy for Epstein-Barr virus-associated lympho-proliferative disorders complicating marrow allografts. Springer Semin. Immuno-Pathol. 20, 445-491.
178. Ossevoort, M. A., Feltkamp, M. C. W., Van Veen, K. J. H., Melief, C. J. M., and Kast, W. M. (1995). Dendritic cells as carriers for a CTL epitope-based peptide vaccine in protection against an HPV16 induced tumor. J. Immunother. 18, 86-94.
179. Ossendorp, F., Eggers, M., Neisig, A., Ruppert, T., Groettrup, M., Sijts, A., Mengede, E., Kloetzel, P. M., Neefjes, J. J., Koszinowski, U., and Melief, C. J. M. (1996). A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity 5, 115-124.
180. Ossendorp, F., Mengedé, E., Camps, M., Filius, R., and Melief, C. J. M. (1998). Specific T helper cell requirement for optimal induction of CTL against MHC class II-negative tumors. J. Exp. Med. 187, 693-702.
181. Overwijk, W. W., Tsung, A., Irvine, K. R., Parkkurst, M., Goletz, T. J., Tsung, K., Carroll, M. W., Liu, C., Moss, B., Rosenberg, S. A., and Restifo, N. P. (1998). Gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self" reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188, 277-286.
182. + T lymphocytes. Proc. Natl. Acad. Sci. USA 96, 2982-2987.
183. Owen-Schaub, L., van Golen, K. L., Hill, L. L., and Price, J. E. (1998). Fas and Fas ligand interactions suppress melanoma. J. Exp. Med. 188, 1717-1723.
184. + T cells upon acute versus peristent viral infection. Immunity 9, 449-457.
185. Pardoll, D. M. (1998). Cancer vaccines. Nature Med. 4, 525-531.
186. Peter M. E., Kischkel, F. C., Scheuerpflug C. G., Medema, J. P., Debatin K. M., and Krammer P. H. (1997). Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur. J. Immunol. 27, 1207-1212.
187. Petersson, M., Charo, J., Salazar-Onfray, F., Noffz, G., Mohaupt, M. Qin, Z., Klein, G., Blankenstein, T., and Kiessling, R. (1998). Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression and poor TAP 1/2 function in the prototype NK target YAC-1. J. Immunol. 161, 2099-2105.
188. + T cells. J. Exp. Med. 189, 757-765.
189. Pitty, R. M., Marsters, S. A., Lawrence, D. A., Roy, M., Kischkel, F. C., Dowd, P., Huang, A., Donahue, C. J., Sherwood, S. W., Baldwin, D. T., Godowski, P. J., Wood, W. I., Gurney, A. L., Hillan, K. J., Cohen, R. L., Goddard, A. D., Botstein, D., and Ashkenazi, A. (1998). Genomic amplification of a decoy receptor for FAS ligand in lung and colon cancer. Nature 396, 699-702.
190. + T cells after gene gun immunization. J. Exp. Med. 188, 1075-1082.
191. Pulaski, B. A., and Ostrand-Rosenberg, S. (1998). Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with MHC class II and B7.1 cell based tumor vaccines. Cancer Res. 58, 1486-1493.
192. Real, L. M., Junenez, P., Canton, J., Kirkin, A., Garcia, A., Abril, E., Zeuthen, J., Ruiz-Cabello, F., and Garrilo, F. (1998). In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele. Int. J. Cancer 75, 317-323.
193. Reichardt, V. L., Okada, C. Y., Liso, A., Benike, C. J., Stockerl-Goldstein, K. E., Engleman, E. G., Blume K. G., and Levy, R. (1999). Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study. Blood 93, 2411-2419.
194. Reimann, J., and Kaufmann, S. H. E. (1997). Alternative antigen processing pathways in anti-infective immunity. Curr. Opin. Immunol. 9, 462-469.
195. Ressing, M. E., Van Driel, W. J., Celis, E., Sette, A., Brandt, R. M. P., Hartman, M., Anholts, J. D., Schreuder, G. M. T., Ter Harmsel, W. B., Fleuren, G. J., Trimbos, J. B., Kast, W. M., and Melief, C. J. M. (1996). Occasional memory CTL responses of patients with human HPV-16 positive cervical lesions against a human HlA-A*0201 restricted E7 encoded epitope. Cancer Res. 56, 582-588.
196. Restifo, N. P., and Rosenberg, S. A. (1999). Recent progress toward the development of recombinant and synthetic vaccines for the treatment of melanoma. Curr. Opin. Oncol. 11, 50-57.
197. Ria, F., Penna, G., and Adorini, L. (1998). Th1 cells induce and Th2 inhibit antigen-dependent IL-12 secretion by dendritic cells. Eur. J. Immunol. 28, 2003-2016.
198. + T-helper and a T-killer cell. Nature 393, 474-478.
199. Riethmüller, G., Holz, E., Schmiok, G., Schiegel, W., Raab, R., Höffken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirche, H., et al. (1998). Monoclonal antibody therapy for resected Duke's C colorectal cancer: Seven year outcome of a multicenter randomized trial. J. Clin. Oncol. 16, 1788-1794.
200. Rock, K. L. (1996). A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 17, 131-137.
201. Romero, P., Cerottini, J. C., and Waanders, G. A. (1998a). Novel methods to monitor antigen-specific CTL responses in cancer immunotherapy. Mol. Med. Today 4, 305-312.
202. Romero, P., Dunbar, P. R., Valenori, D. Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J. L., Lienard, D., Cerottini, J. C., and Cerundolo, V. (1998b). Ex vivo staining of metastatic lymph nodes by MHC class I tetramers reveals high numbers of antigen-experienced tumor-specific CTL. J. Exp. Med. 188, 1641-1650.
203. Rongcun, Y., Salazar-Onfray, F., Charo, J., Malmberg, K. J., Evrin, K., Maes, H., Kono, K., Hising C., Petersson M., Larsson, O., Lan, L., Appella E., Sette A., Celis E., and Kiessling R. (1999). Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J. Immunol. 163, 1037-1044.
204. Rooney, C. M., Smith, C. A., Ng, C. Y. C., Loftin, S. K., Sixberg J. W., Gan, Y., Srivastava, D. K., Bowman, L. C., Krance, R. A., Brenner, M. K., and Heslop, H. E. (1998). Infusion of CTL for the prevention and treatment of EB V-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549-1555.
205. Röpke, M., Hald, J., Guldenberg, P., Zeuthen, J., Norgaard, L., Fugger, L., Svejgaard, A., Van der Burg. S. H., Nijman, H. W., Melief, C. J. M., and Claesson, M. H. (1996). Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA 93, 14704-14707.
206. Rosenberg, S. A., Yanelli, J. R., Yang, J. C., Topalian, S. L., Schwarzentruber, D. J., Weber, J. S., et al. (1994). Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and IL-2. J. Natl. Cancer Inst. 86, 1159-1166.
207. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwartz, S. L., Spiess, P. J. et al. (1998). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327.
208. Rosenberg, S. A. (1999). A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281-287.
209. Roskrow, M. A., Dilloo, D., Suzuki, N., Zhong, W., Rooney, C. M., and Brenner, M. K. (1999). Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk. Res. 23, 549-557.
210. Ruiz-Cabello, F., and Garrido, F. (1998). HLA and cancer: From research to clinical impact. Immunol. Today 19, 539-542.
211. Sadovnikova, E., and Stauss, H. J. (1996). Peptide-specific cytotoxic Tlymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 93, 13114-13118.
212. Sadovnikova, E., Jopling, L. A., Soo, K. S., and Stauss, H. J. (1998). Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur. J. Immunol. 28, 193-200.
213. Sahin, U., Türeci, Ö., Schmitt, H., Cochlovius, B., Johannes, T., Schmitts, R., Stenner, F., Luo, G., Schobert, I., and Pfreundschuh, M. (1995). Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92, 11810-11813.
214. Sallusto, F., and Lanzavecchia, A. (1999). Mobilizing dendritic cells for tolerance, priming and chronic inflammation. J. Exp. Med. 189, 611-614.
215. Samanci, A., Yi, Q., Fagerberg, J., Strigard, K., Smith, G., Rudén, U., Wahren, B., and Mellstedt, H. (1998). Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant careinoembryonic antigen. Cancer Immunol. Immunother. 47, 131-142.
216. Saoulli, K., Lee, S. L., Cannons, J. L., Yeh, W. C., Santana, A., Goldstein, M. D., Bangia, N., De Benedette, M. A., Mak, T. W., Choi, Y., and Watts, T. H. (1998). CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1 BB ligand. J. Exp. Med. 187, 1849-1862.
217. Scaffidi, C., Schmitz I., Krammer P. H., and Peter, M. E. (1999). The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 274, 1541-1548.
218. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., and Peter, M. E. (1998). Two CD95 (APO-I/FAS) signalling pathways. EMBO J. 17, 1675-1687.
219. Schirle, M., Keilholz, W., Gouttefangeas, C., Weber, B., Dumrese, T., Becker, H. D., Stevanovic, S., and Rammensee, H. G. (2000). Identification of tumor-associated MHC class I ligands by a novel T cell independent approach. Submitted for publication.
220. Schirmbeck, R., Wild, J., and Reimann, J. (1998). Similar as well as distinct MHC class I-binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen. Eur. J. Immunol. 28, 4149-4161.
221. Schoenberger, S. P., and Sercarz, E. E. (1996). Harnessing self-reactivity in cancer immunotherapy. Semin. Immunol. 8, 303-309.
222. Schoenberger, S. P., Jonges, L. E., Mooijaart, R., Hartgers, F., Toes, R. E. M., Kast, W. M., Melief, C. J. M., and Offringa, R. (1998a). Efficient direct priming of tumor-specific CTL in vivo by an engineered APC. Cancer Res. 58, 3094-3100.
223. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R., and Melief, C. J. M. (1998b). T cell help for cytotoxic T lymphocyte responses is mediated by CD40-CD40 L interactions. Nature 393, 480-483.
224. Schreurs, M. W. J., de Boer, A., Figdor, C. G., and Adema, G. J. (1998). Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces CTL-mediated tumor protection. Cancer Res. 58, 2509-2514.
225. Schurmans, L. R. H. M., Den Boer, A., Diehl, L., V.d. Voort, E. I. H., Kast, W. M., Melief, C. J. M., Toes, R. E. M., and Jager M. J. (1999). Successful immunotherapy of an intraocular tumor in mice. Cancer Res., 59, 5250-5254.
226. + T cells to an antigen that no longer serves as a target. J. Exp. Med. 178, 933-940.
227. Shapiro, A., Imreh, M., Leonchiks, A., Imreh, S., and Masucci, M. G. (1998). A minimal glycine-alanine repeat prevents the interaction of ubiquitinated Iκβα with the proteasome: A new mechanism for selective inhibition of proteolysis. Nature Med. 4, 939-944.
228. Sherman, L. A., Theobald, M., Morgan, D., Hernandez, J., Bacik, I., Yewdell, J., Bennink, J., and Biggs, J. (1998). Strategies for tumor elimination by cytotoxic T lymphocytes. Crit. Rev. Immunol. 18, 47-54.
229. Shinde, S., Wu, Y., Guo, Y., Niu, Q, Xu, J., Grewal, I. S., Flavell, R. A., and Liu, Y. (1996). CD40L is important for induction of, but not response to, costimulatory activity. ICAM-1 as the second costimulatory molecule rapidly upregulated by CD40L. J. Immunol. 157, 2764-2768.
230. Sigal, L. J., Crotty, S., Andino, R., and Rock, K. L. (1999). CTL immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398, 77-80.
231. Simpson, E., Roopenian, D., and Goulmy, E. (1998). Much ado about minor histocompatibility antigens. Immunol. Today 19, 108-112.
232. + Hodgkin's disease. Blood 89, 1978-1986.
233. Skipper, J. C. A., Gulden, P. H., Hendrickson, R. C., Harthun, N., Caldwell, J. A., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L. (1999). Mass-spectrometric evaluation of HLA-A *0201-associated peptides identifies dominant naturally processed forms of CTL epitopes MART-1 and gp100. Int. J. Cancer 82, 669-677
234. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ulrich, A., and McGuire, W. L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
235. Snijders, A., Kalinski, P., Hilkens, C. M. U., and Kapsenberg, M. L. (1998). High-level IL-12 production by human dendritic cells requires two signals. Int. Immunol. 10, 1593-1598.
236. Sogn, J. A. (1998). Tumor immunology: The glass is half full. Immunity 9, 757-763.
237. Soiffer, R., Lynch, T. Mihm, M., and 24 others (1998). Vaccination with irradiated autologous melanoma cells engineered to secrete human GM-CSF generates potent anti-tumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 95, 13141-13146.
238. + T cell tolerance to T cell priming through in vivo ligation of CD40. Nature Med. 5, 780-787.
239. Starzl, T. E., and Zinkernagel, R. M. (1998). Antigen localization and migration in immunity and tolerance. N. Engl. J. Med. 339, 1905-1913.
240. Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., and Levitsky, H. (1998). Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95, 1178-1183.
241. Stockert, E., Jäger, E., Chen, Y. T., Scanlan, M. J., Gout, I., Karbach, J. Arand, M., Knuth, A., and Old, L. J. (1998). A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187, 1349-1354.
242. Stoltze, L., Dick, T. P., Deeg, M., Pömmerl, B., Rammensee, H. G., and Schild, H. (1998). Generation of the VSV nucleoprotein CTL epitope requires proteasome-dependent and -independent proteolytic activities. Eur. J. Immunol. 28, 4029-4036.
243. Strasser, A., Harris, A. W., Huang, D. C., Krammer, P. H., and Cory, S. (1995). Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 14, 6136-6147.
244. Syrengelas, A. D., and Levy. R. (1999). DNA vaccination against the idiotype of a murine B cell lymphoma: Mechanism of tumor protection. J. Immunol. 162, 4790-4795.
245. Takahashi, C., Mittler, R. S., and Vella, A. T. (1999). Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 162, 5037-5040.
246. Tempero, K. M., VanLith, M. L., Morikane, K., Rowse, G. J., Gendler, S. J., and Hollingsworth, M. A. (1998). CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J. Immunol. 161, 5500-5506.
247. Theobald, M., Ruppert, T., Kuckelkorn, U., Hernandez, J., Hänssler, A., Ferreira, E. A., Liewer, U., Biggs, J., Levine, A. J., Huber, C., Koszinowski, U. H., Kloetzel, P. M., and Sherman, L. A. (1998). J. Exp. Med. 188, 1017-1028.
248. Tighe, H., Corr, M., Roman M., and Raz, E. (1998). Gene vaccination: Plasmid DNA is more than just a blueprint. Immunol. Today 19, 89-97.
249. Tilkin, A. F., Lubin, R., Soussi, T., et al. (1995). Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur. J. Immunol. 25, 1765-1769.
250. Toes, R. E. M., Blom, R. J. J., Van der Voort, E., Offringa, R., Melief, C. J. M., and Kast, W. M. (1996a). Protective anti-tumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res. 56, 3782-3789.
251. Toes, R. E. M., Offringa, R., Blom, R. J. J., Melief, C. J. M., and Kast, W. M. (1996b). Peptide vaccination can lead to enhanced tumor growth through specific tolerance induction. Proc. Natl. Acad. Sci. USA 93, 7855-7860.
252. Toes, R. E. M., Blom, R. J. J., Offringa, R., Kast, W. M., and Melief, C. J. M. (1996c). Functional deletion of tumor-specific CTL induced by peptide immunization can lead to the inability to reject tumors. J. Immunol. 156, 3911-3918.
253. Toes, R. E. M., Hoeben, R. C., Van der Voort, E. I., Melief, C. J. M., and Offringa, R. (1997a). Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc. Natl. Acad. Sci. USA 94, 14660-14665.
254. Toes, R. E. M., Schoenberger, S. P., Van der Voort, E. I. H., Kast, W. M., Hoeben, R. C., Melief, C. J. M., and Offringa, K. (1997b). Activation or frustration of anti-tumor responses by T cell based immune modulation. Semin. Immunol. 9, 323-327.
255. Toes, R. E. M., van der Voort, E. I. H., Schoenberger, S. P., Drijhout, J. W., van Blooijs, L., Storm, G., Kast, W. M., Offringa, K., and Melief, C. J. M. (1998a). Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160, 4449-4456.
256. Toes, R. E. M., Schoenberger, S. P., Van der Voort, E. I. H., Offringa, R., and Melief, C. J. M. (1998b). CD40-CD40 L interactions and their role in CTL priming and anti-tumor immunity. Semin. Immunol. 10, 443-448.
257. + T cells and their role in antitumor immune responses. J. Exp. Med. 189, 753-756.
258. Tollefson, A. E., Herimston, T. W., Lichtenstein, D. L., Colle, C. F., Tripp, R. A., Dimitrov, T., Toth, K., Wells, C. E., Doherty, P. C., and Wold, W. S. M. (1998). Forced degradation of fas inhibits apoptosis in adenovirus-infected cells. Nature 392, 726-730.
259. + T cells recognize non-mutated HLA-DR-restricted tyrosinase epitopes J. Exp. Med. 183, 1965-1971.
260. Tsang, K. Y., Zhu, M., Nieroda, C. A., Correale, P., Zaremba, S., Hamilton, J. M., Cole, D., Lam, C., and Schlom, J. (1997). Phenotypic stability of a cytotoxic T cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin. Cancer Res. 3, 2439-2449.
261. Tuting, T., Wilson, C. C., Martin, D. M., Kasamon, Y. L., Rowles, J., Ma, D. I., Slingluff, C. L., Jr, Wagner, S. N., van der Bruggen, P., Baar, J., Lotze, M. T., and Storkus, W. J. (1998). Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J. Immunol. 160, 1139-1147.
262. Van Baren, N., Chambost, H., Ferrant, A., Michaux, L., Ikeda, H., Millard, I., Olive, D., Boon, T., and Coulie, P. G. (1998). Prame, a gene encoding an antigen recognized by cytolytic T cells, is expressed in acute leukaemia cells. Br. J. Haematol. 102, 1376-1379.
263. Van Beizen, N., Hupkes, P. E., Doekharan, D., Hoogeveen-Westerveld, M., Dorssers, L. C., and van't Veer, M. B. (1997). Detection of minimal disease using rearranged immunoglobulin heavy chain genes from intermediate- and high-grade malignant B cell non-Hodgkins lymphoma. Leukemia 11, 1742-1752.
264. Van den Eynde, B., and Van der Bruggen, P. (1997). T cell-defined tumor antigens. Curr. Opin. Immunol. 9, 684-693.
265. Van der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M., and Melief, C. J. M. (1996). Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156, 3308-3314.
266. Van der Burg, S. H., Offringa, R., and Melief, C. J. M. (1999). Viral cancer antigens. In "Cancer" (V. T. De Vita, S. Hellman, and S. A. Rosenberg, eds.), pp. 514-526. Lippincott-Raven, Philadelphia.
267. Van Elsas, A., van der Burg, S. H., van der Minne, C. E., Borghi, M., Mourer, J. S., Melief, C. J. M., and Schrier, P. I. (1996). Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A *0201 binding peptides from the melan-A/MART-1 self antigen. Eur. J. Immunol. 26, 1683-1689.
268. Van Elsas, A., Hurwitz, A. A., and Allison, J. P. (1999). Combination immunotherapy of B16 melanoma using anti-CTLA4 and GM-CSF producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366.
269. Van Hall, T., van de Rhee, N. E., Schoenberger, S. P., Vierboom, M. P., Verreck, F. Á., Melief, C. J., and Offringa, K. (1998). Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes. Cancer Res. 58, 3087-3093.
270. Vierboom, M. P. M., Nijman, H. W., Offringa, R., Van der Voort, E., Van Hall, T., Van den Broek, L., Fleuren, G. J., Kenemans, P., Kast, W. M., and Melief, C. J. M. (1997). Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186, 695-704.
271. Vierboom, M. P. M., Gabrilovich, D. I., Offringa, R., Kast, W. M., and Melief, C. J. M. (1999). p53: A target for T cell-mediated immunotherapy. In "Peptide-based vaccines" (W. M. Kast, ed.). Landes Biosciences.
272. Vinay, D. S., and Kwon, B. S. (1998). Role of 4-1 BB in immune responses. Semin. Immunol. 10, 481-489.
273. Visseren, M. J. W., Van Elsas, A., van der Voort, E., Ressing, M. E., Kast, W. M., Schrier, P. I., and Melief, C. J. M. (1995). CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol. 154, 3991-3998.
274. Vogel, L. A., and Noelle, R. J. (1998). CD40 and its crucial role as a member of the TNFR family. Semin. Immunol. 10, 435-442.
275. Weinberg, A. D., Vella, A. T., and Croft, M. (1998). OX-40: Life beyond the effector T cell stage. Semin. Immunol. 10, 471-480.
276. WHO Report of a technical meeting. (1999). The current status of development of prophylactic vaccines against human papillomavirus infection. Genoa, Italy.
277. Wood, P., and Elliott, T. (1998). Glycan-regulated antigen processing of a protein in the endoplasmic reticulum can uncover cryptic CTL epitopes. J. Exp. Med. 188, 773-778.
278. Ying, H., Zaks, T. Z., Wang, R.-F., Irvine, K. R., and Restifo, N. P. (1999). Cancer therapy using a self-replicating RNA vaccine. Nature Med. 5, 823-827.
279. York, I. A., and Rock, K. L. (1996). Antigen processing and presentation by class I major histocompatibility complex. Annu. Rev. Immunol. 14, 369-396.
280. Yoshino, I., Peoples, G. E., Goedegebuure, P. S., Maziarz, R., and Eberlein, T. J. (1994). Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J. Immunol. 152, 2393-2400.
281. Zaks, T. Z., and Rosenberg, S. A. (1998). Immunization with a peptide epitope (p 369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu tumors. Cancer Res. 58, 4902-4908.
282. Zaremba, S., Barraga, E., Zhu, M. Z., Soares, N., Tsang, K. Y., and Schlom, J. (1997). Identification of an enhancer agonist CTL peptide from human carcinoembryonic antigen. Cancer Res. 57, 4570-4577.
283. Zhu, X., Tommasino, M., Vousden, K., Sadovnikova, E., Rappuoli, R., Crawford, L., Kast, W. M., Melief, C. J. M., Beverley, P. C. L., and Stauss, H. J. (1995). Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of HPV16. Scand. J. Immunol. 42, 557-563.